Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Orchestra BioMed Holdings (OBIO) EBITDA (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed EBITDA for 4 consecutive years, with $6.3 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 138.64% to $6.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$52.7 million through Dec 2025, up 13.56% year-over-year, with the annual reading at -$52.7 million for FY2025, 13.56% up from the prior year.
  • EBITDA for Q4 2025 was $6.3 million at Orchestra BioMed Holdings, up from -$20.8 million in the prior quarter.
  • The five-year high for EBITDA was $6.3 million in Q4 2025, with the low at -$20.8 million in Q3 2025.
  • Average EBITDA over 4 years is -$12.3 million, with a median of -$13.0 million recorded in 2023.
  • The sharpest move saw EBITDA crashed 91.43% in 2023, then surged 138.64% in 2025.
  • Over 4 years, EBITDA stood at -$9.8 million in 2022, then tumbled by 30.67% to -$12.8 million in 2023, then dropped by 27.06% to -$16.2 million in 2024, then soared by 138.64% to $6.3 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at $6.3 million, -$20.8 million, and -$19.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.